IFF International Flavors & Fragrances
A post-divestiture flavor house where value depends on margins catching up with Givaudan, not on growth.
The story
IFF is a scale player in flavors, fragrances, food ingredients and biosciences. Its moat comes from formulation know-how, regulatory files and customer co-development that make it sticky inside the products of consumer staples companies. After the debt-funded N&B merger destroyed value, the company is now in a repair and portfolio-pruning phase: Pharma Solutions has been sold, debt is coming down, and the remaining business is a mature, low-single-digit grower. Its value depends on rebuilding margins toward peer levels, not on growth.
The fall in TTM revenue from 10.9B to 9.2B comes from the Pharma Solutions divestiture, not from organic decline, so I keep 3.5% growth off the smaller base. I raise sales-to-capital from 0.9 to 1.6, a 78% increase, because the reported 0.46 is inflated by merger goodwill: capex now runs below D&A, so incremental capital needs are modest. Last time's value was 70% below the market, which signaled this driver was too punitive. I lift target margin slightly, from 15.5% to 16.5%, because amortization of acquired intangibles rolls off and the divestiture leaves a higher-margin mix, which puts IFF between Symrise and Givaudan.
Value drivers
| Revenue growth (Y1) | 3.5% |
| Terminal growth | 3.0% |
| Forecast horizon | 7y |
| Target operating margin | 16.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 1.00 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 4.05B |
| PV of terminal value | 8.75B |
| Equity value | 7.22B |
| ÷ shares → per share | $28.82 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 9.55B | 3.5% | 6.3% | 475.27M | 201.82M | 273.45M | 249.89M |
| 2 | 9.88B | 3.4% | 8.9% | 690.43M | 203.91M | 486.53M | 406.30M |
| 3 | 10.20B | 3.3% | 11.4% | 919.01M | 205.73M | 713.28M | 544.34M |
| 4 | 10.54B | 3.2% | 14.0% | 1.16B | 207.28M | 953.85M | 665.20M |
| 5 | 10.87B | 3.2% | 16.5% | 1.42B | 208.52M | 1.21B | 770.07M |
| 6 | 11.20B | 3.1% | 16.5% | 1.46B | 209.47M | 1.25B | 728.62M |
| 7 | 11.54B | 3.0% | 16.5% | 1.50B | 210.09M | 1.29B | 688.83M |
Key risks
- Margin repair stalls as volume weakness at consumer staples customers and destocking persist
- Further goodwill impairments or poorly priced divestitures (for example in Food Ingredients) destroy more capital
- Leverage of about 5.4B net debt limits flexibility if EBITDA disappoints
Catalysts
- Further portfolio pruning that cuts debt and leaves a higher-margin taste and scent core
- GAAP operating margin moving visibly toward mid-teens as amortization declines and productivity programs deliver